MarketVIEW Vaccine Technology & Platforms  ·  January 2019 edition

mRNA & Nucleic Acid-Based
Vaccines Forecast

In January 2019, more than a year before COVID-19 forced the fastest vaccine development effort in history, this report set out mRNA's "potential" as a platform for cancer, infectious disease and protein-replacement vaccines. That potential is no longer speculative. Comirnaty and Spikevax proved the platform could be developed and manufactured at unprecedented speed and scale, and it has since diversified well beyond COVID-19: Moderna's mResvia is a licensed RSV vaccine, mFLUSIVA is the first approved mRNA flu vaccine, and Arcturus/CSL's Kostaive has brought a second-generation, self-amplifying RNA vaccine to market. This is a comprehensive, wide geography review of that now-proven and rapidly diversifying infectious-disease platform, its full company and alliance landscape, and the self-amplifying and circular RNA technologies queuing up behind it.

Platform Validated at Global Scale 6 Approved mRNA/saRNA Vaccines Self-Amplifying RNA Now Marketed Forecast Horizon to 2035
Product catalogue
VAMV079
January 2019 edition

Format
Executive presentation + Excel model
Coverage
Global, company/alliance landscape
Indications
Respiratory combinations, HIV, Lyme disease, next-gen platforms
Forecast horizon
To 2035
Approach
Technology & competitive landscape analysis
Base edition
January 2019
Availability
Syndicated / bespoke
6
Approved mRNA/self-amplifying RNA
infectious-disease vaccines marketed worldwide
10+
Active clinical-stage nucleic-acid
infectious-disease candidates tracked
2020
Year mRNA vaccines were first
authorised, the platform's founding proof point
7
Major companies & alliances tracked
across the mRNA/nucleic-acid landscape
Technology background

From a speculative technology bet to a proven, diversifying platform

mRNA and nucleic acid-based vaccines were, in January 2019, a genuinely speculative wager. This review sets out the underlying mechanism, the historical arc from that speculative framing through COVID-19's proof of concept to today's diversified pipeline, and the next generation of technologies now emerging behind it.

Platform mechanism & 2025/26 landscape update

Technology overview - mRNA, self-amplifying RNA and circular RNA

mRNA vaccines work by encapsulating a synthetic messenger RNA strand, encoding a target antigen, inside a lipid nanoparticle (LNP). Once injected, the LNP fuses with host cells and delivers the mRNA into the cytoplasm, where the cell's own ribosomes translate it into antigen protein, triggering both humoral (antibody) and cellular immune responses without the antigen ever having to be manufactured, purified or delivered as protein itself. This report's original January 2019 edition flagged the early technical obstacles to that approach: mRNA's inherent instability outside a cell, and the complexity of loading it into dendritic cells for efficient antigen presentation. LNP and cationic nanoparticle encapsulation had, even then, begun to resolve both problems, and landmark studies were already showing that directly injected, encapsulated mRNA was safe and immunogenic in healthy and cancer patients alike.

What was "potential" in January 2019 became proof of concept within a year. SARS-CoV-2 emerged from Wuhan in December 2019, and Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna) became the first mRNA vaccines ever authorised, in December 2020, at a speed and scale no prior vaccine platform had achieved. Six years on, the platform has moved decisively beyond that single proof point. Moderna's mResvia became a licensed RSV vaccine in 2024, with expanded approval into at-risk younger adults following in 2025. mFLUSIVA (mRNA-1010) became the first mRNA-based influenza vaccine approved anywhere, cleared by the FDA on 5 August 2026 for adults 50 and over after Phase 3 FLUENT trial data across more than 40,000 participants. A combination flu/COVID candidate, mRNA-1083, was authorised in the European Union as mCOMBRIAX in early 2026, the world's first licensed influenza/COVID-19 combination vaccine, even as its US filing remains under review pending further efficacy data. The platform's founding products also remain on active annual review: in late August 2026 the FDA approved updated 2026-27 season formulations of Comirnaty and Spikevax targeting the circulating XFG variant, with routine recommendation still confined largely to adults aged 65 and over and other higher-risk groups rather than the general population. Regulatory clearance has outpaced formal US immunisation policy, however: a federal court blocked HHS Secretary Robert F. Kennedy Jr.'s 2026 restructuring of the Advisory Committee on Immunization Practices (ACIP), and with no new members nominated, the committee had issued no new vaccine recommendations as of late October 2026, leaving mFLUSIVA and the updated Comirnaty/Spikevax formulations without an ACIP recommendation and insurers under no legal requirement to cover them until one is issued.

A genuine second generation of nucleic-acid technology is now emerging behind that first wave. Self-amplifying RNA (saRNA) encodes not just the antigen but also a viral replicase enzyme, allowing the mRNA to copy itself inside the cell and generate a strong immune response from a substantially smaller dose. Arcturus Therapeutics and CSL's Kostaive, approved in Japan and subsequently by the European Commission (February 2025) and the UK's MHRA (January 2026), is the field's first approved saRNA vaccine and a direct, working answer to this report's 2019 question about mRNA's next iteration. Circular RNA (circRNA) is a further step again: closed-loop RNA molecules engineered to resist the exonuclease degradation that limits linear mRNA's durability, potentially enabling longer, more durable antigen expression from a single dose. Orna Therapeutics' collaboration with Merck spans infectious-disease and oncology circRNA vaccines, and Eli Lilly's pending acquisition of Orna, announced in February 2026 for up to 2.4 billion US dollars, is a clear signal that major pharma now treats circRNA as a maturing platform rather than a speculative one.

2026 6 approved mRNA/saRNA infectious-disease vaccines worldwide  |  Kostaive approved in Japan, EU & UK  |  circRNA entering the clinic via Merck/Orna  |  mFLUSIVA the first approved mRNA flu vaccine (5 August 2026)  |  Comirnaty & Spikevax 2026-27 formulations FDA-approved (Aug 2026)
Product & competitor landscape

A crowded, actively-triaged company and alliance landscape

Every major vaccine developer now has an infectious-disease mRNA or nucleic-acid programme, but 2024 to 2026 has also brought sharp portfolio triage, most visibly at Moderna, alongside genuine next-generation progress at Arcturus and in circular RNA. Distinguishing approved, active and discontinued programmes is central to reading this landscape correctly.

  • ModernaApproved & marketed (multiple)
    mResvia (RSV, approved 2024, expanded 2025 to at-risk adults aged 18 to 59) and mFLUSIVA (mRNA-1010, the first mRNA flu vaccine, FDA approved 5 August 2026 for adults 50 and over) are both now marketed. The combination flu/COVID candidate mRNA-1083 was authorised in the EU as mCOMBRIAX in early 2026, though its US filing was withdrawn in 2025 pending further Phase 3 flu efficacy data. Moderna's Lyme disease candidates mRNA-1982 and mRNA-1975 remain active, now in Phase 2, even as the company has cut R&D spend by around 31 percent and deprioritised numerous other infectious-disease programmes since 2024, including endemic-coronavirus, paediatric RSV and HSV therapeutic candidates. In November 2026, WHO expert groups also backed Moderna's Ebola vaccine candidate mRNA-1469 (targeting the Bundibugyo strain, in Phase 1 trials in Canada) for inclusion in the Tumaini active-outbreak efficacy trial in the Democratic Republic of Congo, the first time an mRNA candidate has entered an efficacy trial during an active Ebola outbreak.
  • Pfizer / BioNTechPhase 3 & early clinical (multiple)
    PF-07926307, a four-strain flu/COVID combination candidate, is in Phase 3 trials, while a first-in-class mRNA shingles vaccine (BNT167), aimed at improving on Shingrix's efficacy and tolerability, is in Phase 1/2. Earlier-stage programmes span H5N1 pandemic-flu preparedness plus HSV, tuberculosis, malaria and mpox candidates within BioNTech's wider infectious-disease pipeline.
  • Arcturus TherapeuticsApproved & marketed (self-amplifying RNA)
    Kostaive (ARCT-154), the field's first self-amplifying mRNA vaccine, is approved and marketed in Japan and has since gained European Commission approval (February 2025) and UK MHRA approval (January 2026), each for adults aged 18 and over. In August 2026, Arcturus and marketing partner CSL Seqirus terminated their collaboration by mutual settlement: Arcturus regained full global rights to Kostaive and the wider infectious-disease portfolio (seasonal and pandemic influenza, RSV and EBV programmes), subject to existing Meiji Seika Pharma arrangements for the 2026-27 season in Japan, alongside a $12 million cash payment from CSL and release from around $16 million of associated R&D liabilities. saRNA's self-replicating design allows a substantially lower dose than conventional mRNA, a genuine second-generation advance on the platform this report tracked as speculative in 2019.
  • GSK (licensed from CureVac)Phase 2-3 (three candidates)
    Under a restructured 2024 licensing agreement worth up to EUR 1.45 billion, GSK took full development and commercialisation control of CureVac's seasonal influenza, COVID-19 (Phase 2) and avian influenza H5 (Phase 1) mRNA candidates, absorbing one of the field's longest-running independent mRNA alliances. The seasonal influenza candidate, a dual haemagglutinin/neuraminidase-antigen design, advanced to a Phase 3 efficacy trial starting September 2026 after positive Phase 2 data (the Flu-028 trial, 971 adults) showed higher immune responses than licensed standard- and high-dose inactivated flu vaccines.
  • CureVacPivoting to oncology (acquisition pending)
    CureVac has agreed to be acquired by BioNTech, a deal expected to complete in 2025/26, with its own infectious-disease candidates already transferred to GSK and its mRNA sequence-optimisation expertise redirected mainly toward BioNTech's oncology pipeline.
  • SanofiMixed: one dropped, one active
    Sanofi's mRNA Center of Excellence, built on its Translate Bio and Tidal Therapeutics acquisitions, abandoned a next-generation mRNA seasonal flu vaccine in January 2026, but continues a Phase 1/2 mRNA vaccine for H5 pandemic-influenza preparedness, with preliminary data the company describes as encouraging.
  • Orna Therapeutics & next-gen circRNAEarly clinical / preclinical
    Circular RNA is emerging as a further next-generation nucleic-acid platform, engineered for greater in vivo durability than linear mRNA. Orna's collaboration with Merck spans infectious-disease and oncology circRNA vaccines, and Eli Lilly's pending acquisition of Orna, announced February 2026 for up to 2.4 billion US dollars, signals that major pharma now views circRNA as a maturing, investable platform.
Platform inflection point
2019 → 2026

What this report called "potential" in January 2019 is now a marketed, diversifying platform. Six mRNA and self-amplifying RNA infectious-disease vaccines are approved somewhere in the world today, spanning COVID-19, RSV and seasonal flu, and a second wave of self-amplifying and circular RNA technologies is already moving through the same company and alliance network. At the same time, Moderna's sharp 2024/25 pipeline reset shows the platform's economics are now being actively triaged rather than uniformly pursued, precisely the competitive-threat versus opportunity trade-off this report has assessed since its first edition. The VacZine Analytics model quantifies that trade-off across every major infectious-disease indication and nucleic-acid technology now in play.

Scope of analysis

Six analytical layers - one technology and competitive picture

This is a genuinely comprehensive report with a global focus, spanning company and alliance mapping, cross-indication pipeline review, technology comparison and competitive-threat strategic analysis across the whole mRNA/nucleic-acid infectious-disease field.

Global company & alliance landscape review

Full mapping of Moderna, Pfizer/BioNTech, Arcturus/CSL, GSK, CureVac, Sanofi and next-generation circRNA players across the mRNA/nucleic-acid infectious-disease field.

Competitor & pipeline review

R&D pipeline tracking across COVID-19, RSV, seasonal and pandemic influenza, HIV, Lyme disease and combination respiratory programmes.

Technology/platform comparison

Side by side comparison of conventional mRNA, self-amplifying RNA (saRNA) and circular RNA (circRNA) delivery and durability characteristics.

Competitive-threat strategic analysis

Opportunity versus competitive-threat scoring for each programme, should it progress to licensure, updating this report's own original 2019 framing.

R&D pipeline tracking

Ongoing tracking of clinical-stage nucleic-acid candidates and their approval, deprioritisation or discontinuation status.

Early decision-making support

Designed as a practical tool for portfolio, investment and market-entry decisions across the mRNA/nucleic-acid infectious-disease category.

Sample analysis

A glimpse of the competitive landscape model

The table below shows a partial view of the indication, company and status framework. Full programme-level detail, competitive-threat scoring and company profiles are in the licensed workbook.

Indication / segmentGeographyCompanyProgramme statusStrategic threat level
Respiratory combination (flu + COVID)European UnionModernaApproved (mCOMBRIAX)High
Self-amplifying RNA, COVID-19Japan / EU / UKArcturus / CSLApproved & marketedHigh
Lyme diseaseUS / EuropeModernaPhase 2Moderate
█████████████████████████████
█████████████████████████████
Full landscape - all programmesAll geographiesAll companiesAll statuses████
Full landscape in the licensed workbook
Global coverage · to 2035 · all mRNA/nucleic-acid infectious-disease programmes
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a structured Excel workbook, built for organisations tracking the mRNA/nucleic-acid infectious-disease platform across companies, technologies and indications.

  • Executive presentation - platform mechanism, historical arc from 2019 to today, and full competitive environment review (~120 slides, refreshed)
  • MS-Excel company/alliance tracking workbook - structured view of every major developer, programme and alliance
  • Technology/platform comparison module - mRNA versus self-amplifying RNA versus circular RNA
  • Competitive-threat strategic analysis - opportunity/threat scoring by programme, this report's original 2019 framing updated
  • R&D pipeline tracker - approval, deprioritisation and discontinuation status across all indications
  • Early decision-making support - target-selection and market-entry guidance for early-stage planning
Target audience

Built for organisations navigating the mRNA/nucleic-acid landscape

Most valuable to teams assessing the mRNA/nucleic-acid infectious-disease opportunity against their own pipeline, BD ambitions or investment thesis, now that the platform spans multiple approved products and technologies.

Vaccine developers

Positioning, technology-choice and competitive-threat assessment for mRNA, saRNA or circRNA candidates at any stage.

Corporate strategy & BD

Validate where the platform's remaining opportunity sits, now that Moderna's triage and Arcturus/CSL's saRNA approval have reset the competitive map.

Investors & analysts

Independent assessment of pipeline risk and technology-platform upside for due diligence across the mRNA/nucleic-acid company set.

Public health & immunisation programmes

Independent context on which approved and pipeline products are relevant to future respiratory and vector-borne immunisation planning.

Researchers & academia

Comprehensive technology and company landscape for grant, translational and platform-comparison research planning.

Market access & policy

Independent briefing on which nucleic-acid platforms and programmes are approaching regulatory and reimbursement decisions.

About this analysis · VAMV079

VacZine Analytics has long standing expertise in infectious diseases, tracking nucleic-acid and mRNA vaccine technologies since our earliest editions of this report, more than a year before COVID-19 delivered the platform's real-world proof of concept. This is a genuinely comprehensive, cross-indication analysis spanning the full company and alliance landscape, not a single product or programme, and it has been well received by clients across the field for the depth of its technology comparison and competitive-threat framing. Few groups have followed the mRNA/nucleic-acid field this closely across so many infectious-disease indications, and that recognised, independent expertise underpins everything in the analysis.

This report was last published in January 2019; any refresh would incorporate the platform's validation at global scale, its diversification into RSV, seasonal flu and respiratory combination products, and the emergence of self-amplifying and circular RNA as genuine next-generation technologies. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV079 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc mRNA/nucleic-acid vaccine analysis, a briefing call is included on request.